Evaluating quality of decision-making processes in medicines’ development, regulatory review and health technology assessment: a systematic review of the literature

• In: Short Communications D1 on Tuesday, 23 May 2017, 11:15-12:30
• At: Stockholm (Sweden) (2017)
• Type: Presentation
• By: BUJAR, Magdalena (Centre for Innovation in Regulatory Science, EC1N8JS, United Kingdom)
• Co-author(s): Magdalena Bujar: Centre for Innovation in Regulatory Science, EC1N8JS, United Kingdom
  Neil McAuslane: Centre for Innovation in Regulatory Science, EC1N8JS, United Kingdom
  Sam Salek: Department of Pharmacy, Pharmacology & Postgraduate Medicine, University of Hertfordshire, Hatfield, United Kingdom
  Stuart Walker: Centre for Innovation in Regulatory Science, EC1N8JS, United Kingdom
  
• Abstract:

  Backgrounds

  Although the quality of decision making in the development, regulatory review and health technology assessment (HTA) influences the delivery of medicines, it is not certain whether suitable techniques exist for formally assessing this within agencies and companies.

  Aims

  To identify current techniques (tools, questionnaires or

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login